Explore New Frontiers with Elysia Group

HEOR in the United States & Asia

Elysia was formed in 2014 to bridge the gaps between commercial and health economic teams by generating value spanning the interest of multiple stakeholders

To solve issues, we take a rigorous academic approach while creating deliverables that are simple, easy to interpret, and focus on advancing the commercial agenda

We have a small, agile, full-time team including PhD modelers and analysts to support day-to-day operations and projects. We also draw from a pool of leading experts in economics and clinical practice

Health Economic Modeling

Standard cost-effectiveness, budget impact, burden disease models, and specialized models such as market sizing, forecasting, and portfolio analysis

Database Analysis

We conduct database analyses from datasets all of the world, and specialize in Taiwan’s National Health Insurance Research Database

Value Dossiers

We develop value dossiers for submission to summarize the available evidence, local epidemiology, and disease burden

Literature Searches

Our literature searches use multiple outlets to answer organizations’ queries and understand trends

  • Issue #2: Go Your Own Way
    March 5, 2017
  • Issue #3: There’s No Place Like Home
    March 5, 2017
  • Cost-Reduction of Palperidone Palmitate
    March 4, 2017
  • Cost-Effectiveness of Linezolid
    March 4, 2017
  • Precision Health Economics
    March 4, 2017
  • Cost-Effectiveness of Pemetrexed
    March 4, 2017
  • Burden of Inaccurate HER2 Testing
    March 4, 2017
  • Predicting Price Changes in Oncology Drugs
    March 4, 2017
  • Pricing Variations Across Countries
    March 4, 2017
  • Markov Chain Transition Matrices
    March 4, 2017
  • Cost-Effectiveness of Retesting HER2
    March 4, 2017
  • Lifetime Burden of Inaccurate HER2 Testing
    March 4, 2017